

Vaccinator Provider's Name: \_\_\_\_\_

## Moderna COVID-19 Vaccine EXAMPLE Competency Exam

Refer to the [EUA Fact Sheet](#) for Healthcare Providers for questions 1-20:

1. According to the Emergency Use Authorization (EUA), the Moderna COVID-19 vaccine can be used in the following individuals:
  - a. 6 months & older
  - b. 12 years & older
  - c. 16 years & older
  - d. 18 years & older
2. NON-THAWED and unpunctured multiple-dose vials should be protected from light and stored at:
  - a. -80°C to -60°C
  - b. -60°C to -20°C
  - c. -50°C to -15°C
  - d. 2°C to 8°C
3. The vaccine can be thawed in the REFRIGERATOR (2°C to 8°C) for \_\_\_\_\_ (depending on vial size) and safely stored for up to \_\_\_\_\_ prior to first use. When ready to administer, let the vial stand at room temperature for 15 minutes.
  - a. 1 to 2 hours; 12 hours
  - b. 2.5 to 3 hours; 30 days
  - c. 1 to 2 hours; 5 days
  - d. 2 to 3 hours; 6 hours
4. Alternatively, the vaccine can be thawed at ROOM TEMP (15°C to 25°C) for \_\_\_\_\_ before administering.
  - a. 30 minutes
  - b. 1 to 1.5 hours
  - c. 3 to 4 hours
  - d. 6 hours
5. Unpunctured vials may be stored between 8°C to 25°C for up to:
  - a. 2 hours
  - b. 6 hours
  - c. 12 hours
  - d. 24 hours
6. After the first dose has been drawn, the vial should be stored between \_\_\_\_\_ and discarded after \_\_\_\_\_.
  - a. -80°C to -60°C; 6 hours
  - b. -80°C to -60°C; 12 hours
  - c. 2°C to 25°C; 6 hours
  - d. 2°C to 25°C; 12 hours
7. The following are appropriate ways to transport vaccine according to the EUA:
  - a. -50°C to -15°C
  - b. 2°C to 8°C (up to 12 hours; do not refreeze)
  - c. Both (a) and (b) are correct
8. The primary series is given as a \_\_\_\_\_ series with the 2<sup>nd</sup> dose ideally given on day \_\_\_\_\_.
  - a. 2-dose; 21
  - b. 2-dose; 28
  - c. 3-dose; 14
  - d. 1-dose; 21
9. The vaccine should be given intramuscularly at what dose?
  - a. 0.5mL for *primary* series
  - b. 0.5mL for *additional* dose (i.e., mod-severely immunocompromised)
  - c. 0.25mL for *booster* dose
  - d. All are correct
10. True/False It is encouraged to interchange with other COVID-19 vaccines to finish the primary series.
11. True/False If a full dose cannot be drawn from a single vial, it is ok to pool vaccine from other vials.
12. True/False After the first dose is withdrawn, record date and time immediately on the vial.
13. True/False This vaccine must be diluted prior to administration.
14. True/False Before drawing up a dose of the vaccine, vigorously shake the vial to properly mix the product.
15. True/False Once thawed, the vaccine should not be refrozen.
16. True/False Non-thawed and unopened vials can be stored on dry ice or below -50°C.
17. True/False Do not puncture the vial stopper more than 20 times.
18. Regarding the "Fact Sheet for Recipients and Caregivers", the vaccination provider MUST:
  - a. Provide a copy of the Fact Sheet
  - b. Direct the recipient/caregiver to [www.modernatx.com/covid19vaccine-eua](http://www.modernatx.com/covid19vaccine-eua) to obtain the Fact Sheet
  - c. Any of the above are correct
  - d. None of the above; providing the Fact Sheet is NOT Required
19. The vaccination provider is responsible for mandatory reporting of the following that occur post-administration of this vaccine to the Vaccine Adverse Event Reporting System (VAERS):
  - a. Vaccine administration errors, even if no adverse event occurred
  - b. Serious adverse events (life-threatening, death, hospitalization, etc.)
  - c. Cases of Multisystem Inflammatory Syndrome (MIS) in adults
  - d. Case of COVID-19 that result in hospitalization or death
  - e. All of the above are correct

**20. The vaccination provider must communicate to the recipient/caregiver information consistent with the “Fact Sheet for Recipients and Caregivers” prior to vaccine administration, including:**

- a. FDA has authorized the emergency use of the vaccine, which is not a fully licensed vaccine
- b. The recipient or caregiver has the option to accept or refuse the vaccine
- c. The significant known/potential risks and benefits of the vaccine, and the extent to which such risks and benefits are unknown
- d. Information about the available alternative vaccines and the risk and benefits of those alternatives
- e. All of the above are correct

**Answers to questions 21-28 can be found on the CDC website regarding Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Authorized in the US by clicking [here](#):**

- 21. True/False** Patients considered moderately to severely immunocompromised per CDC should be offered an additional dose (i.e., 3<sup>rd</sup> dose) of this vaccine at least 28 days after completing the series.
- 22. True/False** Patients who are immunocompromised, pregnant, breast-feeding, or have history of a resolved COVID-19 infection can generally be offered this COVID vaccine.
- 23. True/False** Patients who are currently on home isolation with suspected or confirmed COVID should come to the clinic to get vaccinated during their quarantine period.
- 24. True/False** An unvaccinated patient just completed home isolation protocol due to resolved COVID-19 infection. However, the patient must wait at least 90 days before receiving the vaccine.
- 25. True/False** Patients  $\geq 18$  years of age that are fully vaccinated with Moderna may receive a heterologous booster dose at least 5 months after the 2<sup>nd</sup> dose of their primary series.
- 26. What is the minimum interval for the second dose of the vaccine to be considered as “valid”?**  
a. 17 days   b. 21 days   c. 24 days   d. 28 days
- 27. Which of the following patients need to be observed for at least 30 minutes post-vaccination (versus the standard 15 minutes) to monitor for the occurrence of immediate adverse reactions?**
- a. History of an immediate allergic reaction of any severity to non-COVID-19 vaccines or injectables
  - b. History of anaphylaxis due to any cause (unrelated to COVID vaccine components)
  - c. History of immediate/severe allergic reaction to polyethylene glycol (PEG)
  - d. Both (a) and (b) are correct – answer (c) would be a contraindication to receiving COVID vaccine
  - e. All of the above are correct
- 28. Which of the following scenarios would be a CONTRAINDICATION to receiving the vaccine?**
- a. 32-year male with history of anaphylaxis to amoxicillin for acute sinusitis
  - b. 67-year old male with history of anaphylaxis following injectable promethazine for nausea
  - c. 42-year old female with history of anaphylaxis to polyethylene glycol (PEG) when preparing for a colonoscopy procedure
  - d. 86-year old female with history of anaphylaxis following a bee sting

---

Vaccine Provider’s Printed Name

Signature

Date